Compare AOUT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | MGNX |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.1M | 94.9M |
| IPO Year | N/A | 2013 |
| Metric | AOUT | MGNX |
|---|---|---|
| Price | $7.79 | $1.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $14.00 | $3.20 |
| AVG Volume (30 Days) | 99.8K | ★ 1.4M |
| Earning Date | 12-09-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,348,000.00 | $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $6.26 | $0.99 |
| 52 Week High | $17.91 | $3.60 |
| Indicator | AOUT | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 43.61 |
| Support Level | $7.61 | $1.32 |
| Resistance Level | $8.16 | $1.45 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 70.53 | 28.26 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.